SC
IMVT icon

Stempoint Capital’s Immunovant IMVT Stock Holding History

Stempoint Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.5M Buy
746,494
+101,535
+16% +$2.63M 3.55% 5
2025
Q4 		$16.4M Sell
644,959
-944,621
-59% -$21.1M 2.81% 10
2025
Q3 		$25.6M Buy
1,589,580
+288,720
+22% +$4.67M 5.13% 4
2025
Q2 		$20.8M Buy
1,300,860
+447,388
+52% +$6.77M 6.68% 2
2025
Q1 		$14.6M Sell
853,472
-265,036
-24% -$5.54M 4.65% 6
2024
Q4 		$27.7M Buy
1,118,508
+447,507
+67% +$12.7M 6.92% 3
2024
Q3 		$19.1M Sell
671,001
-340,878
-34% -$10.1M 5.73% 4
2024
Q2 		$26.7M Buy
1,011,879
+384,651
+61% +$10.9M 7.85% 3
2024
Q1 		$20.3M Buy
627,228
+305,213
+95% +$11.1M 5.36% 5
2023
Q4 		$13.6M Buy
+322,015
New +$11.8M 3.62% 5

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Stempoint Capital's IMVT Position: Q1 2026 in Review

Stempoint Capital increased its Immunovant (IMVT) stake by 16% in Q1 2026, buying an estimated $2.63M and bringing the position to 746,494 shares worth $18.5M. The position accounts for 3.55% of the portfolio, ranked #5.

Stempoint Capital first reported a position in IMVT in Q4 2023 and has held it in 10 quarters since. The position peaked at $27.7M in Q4 2024. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Stempoint Capital held 746,494 shares of Immunovant worth $18.5M as of Q1 2026.
  • Stempoint Capital bought 101,535 Immunovant shares in Q1 2026, an estimated $2.63M.
  • Immunovant made up 3.55% of Stempoint Capital's portfolio in Q1 2026, its #5 holding.
  • Stempoint Capital first reported a position in Immunovant in Q4 2023 and has held it in 10 quarters since.
  • Stempoint Capital's Immunovant position peaked at $27.7M in Q4 2024.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.